Open Access

Airway reactivity and sphingolipids—implications for childhood asthma

Molecular and Cellular Pediatrics20152:13

DOI: 10.1186/s40348-015-0025-3

Received: 12 October 2015

Accepted: 25 November 2015

Published: 4 December 2015

Abstract

Asthma is a clinically heterogeneous disorder, whose onset and progression results from a complex interplay between genetic susceptibility, allergens, and viral triggers. Sphingolipids and altered sphingolipid metabolism have emerged as potential key contributors to the pathogenesis of asthma. Orosomucoid-like 3 gene (ORMDL3) and the asthma susceptibility locus 17q21 have been strongly and reproducibly linked to childhood asthma, but how this gene is functionally linked to asthma is incompletely understood. ORMDL proteins play an integral role in sphingolipid homeostasis and synthesis, and asthma-associated ORMDL3 polymorphisms have been associated with early viral respiratory infections and increased risk of asthma. ORMDL proteins act as inhibitors of serine palmitoyl-CoA transferase (SPT), the rate-limiting enzyme for de novo sphingolipid synthesis, and decreased sphingolipid synthesis through SPT increases airway hyperreactivity, which is independent of allergy or inflammation. In allergic models of asthma, the sphingolipid mediators sphingosine-1-phosphate (S1P) and ceramide have been shown to be important signaling molecules for airway hyperreactivity, mast cell activation, and inflammation. This review will highlight how sphingolipids and altered sphingolipid metabolism may contribute towards the underlying mechanisms of childhood asthma.

Keywords

Sphingolipids Asthma Airway hyperreactivity ORMDL3 Rhinovirus SPT

Introduction

Asthma is a chronic airway disease characterized by reversible airway obstruction, chronic inflammation, mucous production, and airway hyperreactivity. Asthma is a common and clinically heterogeneous disorder and poses huge costs to society [1]. The risk for asthma is determined in infancy and childhood, it is highly heritable, and the phenotypes are conferred by both genetic susceptibility and environmental exposures [2, 3]. Asthma exacerbations are triggered by environmental stimuli, most often respiratory viruses and allergens. Allergic sensitization commonly occurs in children with asthma, although up to half of those with mild to moderate disease will be non-allergic [4] and will respond poorly to current therapies which focus primarily on the inflammatory and allergic components of the disorder [5]. The variation in phenotypes suggests distinct underlying pathophysiology, and asthma is increasingly being viewed as a syndrome rather than a single disease [3].

For most asthma types, a genetic predisposition is present and essential for the “asthmatic reaction” to environmental stimuli. Over 100 genes have been identified in association with asthma [2]; among them, the orosomucoid-like 3 gene (ORMDL3) and the associated 17q21 locus have emerged through genome-wide association studies as likely contributors to the genetic susceptibility and underlying pathogenesis of asthma. While the functions of ORMDL3 are incompletely understood, it is known to be involved in sphingolipid metabolism and de novo sphingolipid synthesis [6], suggesting altered sphingolipid metabolism as a contributing factor in asthma. Ceramides and sphingosine-1-phosphate (S1P) have been the most extensively studied sphingolipids and are important bioactive signaling molecules [6, 7]. In addition to their role in asthma, sphingolipids have been associated with other pulmonary disorders including chronic obstructive pulmonary disease (COPD)/emphysema, cystic fibrosis, vascular permeability, and acute lung injury [8].

Review

Sphingolipids and asthma

Sphingolipids are a diverse and complex category of lipids due to their numerous variations in their sphingoid bases, fatty acids, and head groups [6, 7, 9]. They are key structural elements in cellular membranes and are essential signaling molecules for a wide range of cellular functions including growth and differentiation, signal transduction, immune response, cell proliferation, and apoptosis [7]. Acylation of the sphingoid backbone by specific ceramide synthases yields different ceramides, which vary by acyl chain length. Ceramide serves as a substrate for the production of complex sphingolipids, including sphingomyelin and glycosphingolipids. Ceramide can be generated via de novo sphingolipid synthesis or can be regenerated from hydrolysis of complex sphingolipids through the recycling pathways [7, 9, 10] (Fig. 1).
https://static-content.springer.com/image/art%3A10.1186%2Fs40348-015-0025-3/MediaObjects/40348_2015_25_Fig1_HTML.gif
Fig. 1

Sphingolipid synthesis. Highlighted are de novo and recycling pathways of sphingolipid metabolism and the alleged inhibitory effect of ORMDL3 on SPT

Most studies of sphingolipids and asthma have focused on inflammatory and allergic mechanisms related to the sphingolipid mediator S1P [1119]. S1P is derived from sphingosine through phosphorylation by two sphingosine kinases (SphK1 and SphK2) which are widely expressed, including in bronchial epithelium and airway smooth muscle cells [20]. Through the activation of different signaling pathways, S1P mediates a diverse set of biological processes, acting as both an intracellular second messenger and as an extracellular ligand for specific cell surface G protein-coupled receptors, S1P1–S1P5 [21]. S1P and SphK have been implicated in airway smooth muscle cell hyperresponsiveness, lung inflammation, and mast cell activation, all key features in the pathogenesis of asthma. S1P and the SphK pathways have therefore been targeted for the development of sphingolipid-based therapeutic agents, though the role of S1P and its receptors remains incompletely understood. For example, the immunomodulating agent FTY720 (Fingolimod), approved for the treatment of multiple sclerosis, attenuates allergen-induced inflammation, as well as airway hyperreactivity in mouse models of asthma [12, 22]. This effect was also shown with N,N-dimethylsphingosine (DMS), an SphK inhibitor [15, 20]. Neither of these has been tested for clinical use in asthma yet.

In the mouse, exogenous systemic administration of S1P resulted in increased contraction of the bronchi, increased airway resistance, as well as mast cell and eosinophil recruitment to the lung [18], and enhanced methacholine-induced contractions in guinea pig tracheal smooth muscle [23]. S1P has also been shown to be important in immunoglobulin E (IgE)-mediated mast cell migration and degranulation [24], allergic asthma, and secretion of pro-inflammatory cytokines [25]. Mast cells play a central role in the development of asthma, and cross-linking of FCεR1, the high-affinity IgE receptor, induces SphK activation and S1P secretion [24, 26].

In humans, S1P levels are significantly increased in bronchioalveolar lavage (BAL) fluid from subjects with asthma following segmental allergen challenge compared to control subjects [11]. Decreased protein levels for S1P1 receptor have been demonstrated in adults with asthma, and polymorphisms in S1P1 have been associated with an increased risk for asthma [19]. In addition, ceramide (C16) levels were noted to be increased in the exhaled breath collection of seriously ill subjects with asthma, compared to healthy controls [22].

Ceramides have also recently been implicated in the pathogenesis of COPD and emphysema. Although not relevant for the pediatric population, Asthma-COPD Overlap Syndrome (ACOS), a poorly identified but increasingly recognized entity, could provide some further clues for the role of sphingolipids in airway diseases. In a joint statement, ACOS has recently been recognized by the Global Initiative for Asthma (GINA www.ginasthma.org) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD www.goldcopd.org) as a distinct clinical entity, encompassing individuals who have clinical symptoms that are characteristic of both asthma and COPD [27]. Like asthma, COPD is characterized by obstruction due to smooth muscle contraction, increased mucus production, and chronic inflammation [27, 28]. Also like asthma, COPD is a heterogeneous disorder with variable clinical phenotypes which is impacted by environmental factors [27, 28]. Cigarette smoke exposure is a major risk factor in developing this disease; however, most smokers do not develop COPD [28] suggestive of an underlying susceptibility to this environmental insult in those patients. Altered sphingolipids and sphingolipid metabolism has been suggested as a possible mechanism in this susceptibility [29].

Lung ceramide levels where shown to be higher in human subjects with emphysema (a specific phenotype of COPD) compared to those without [30], and the expression of multiple species of ceramides, dihydroceramides, glycosphingolipids, and sphingomyelins were shown to be significantly higher in smokers with COPD than those in non-smokers [29]. In another recent study looking at the association between sphingolipid species and different COPD phenotypes, plasma sphingolipids were shown to be inversely related to emphysema severity and positively associated with severe COPD exacerbations [31].

ORMDL3 and asthma

ORMDL3 on chromosome 17 (17q21) has been strongly and consistently linked to asthma in multiple ethnic groups [3241]. Single nucleotide polymorphisms (SNPs) within the 17q21 asthma susceptibility locus achieved genome-wide level significance with childhood-onset asthma [42] and have been since widely replicated. Moffat et al. showed that in Epstein-Barr virus-transformed lymphoblastoid cell lines, transcript levels of ORMDL3 were positively associated with rs7216389, the SNP with the strongest association with childhood asthma [38]. This suggested that variants at this asthma susceptibility locus may regulate ORMDL3 expression, having also been confirmed in rhinovirus-infected blood cells [43].

Polymorphisms at the ORMDL3 locus have been associated with increased risk for asthma [34, 4446], severe asthma [32, 47], and early viral respiratory infections in asthma [40]. Infection with respiratory viruses is a well-known risk factor for persistent wheezing and a risk factor for asthma later in life [40, 43]. Variants at the 17q21 locus are shown to enhance the association between early respiratory infections and childhood asthma [37, 40, 43]. In particular, infections with human rhinovirus (HRV), the most common trigger of asthma exacerbations [48, 49], are associated with a more than 10-fold increased odds ratio for childhood asthma in children who carry the asthma-associated ORMDL3 genotype [43]. Interestingly, this effect was not seen in association with respiratory syncytial virus (RSV), a commonly associated virus with early-onset wheezing and bronchiolitis in infants and children [43]. Although infection with HRV is associated with increased risk for the development of asthma [40, 43, 50], only a portion of children exposed go on to develop the disease suggesting that the host genotype likely plays a role [43]. In another study, Smit et al. showed that the association between early viral infection and asthma had a greater than twofold difference in odds ratio in individuals who were homozygous for the risk-related alleles at the ORMDL3-associated SNPs [40]. This association was further enhanced when children with risk-related variants were exposed to tobacco smoke in early life [34, 40].

In mouse lungs, ORMDL3 expression can be increased by a variety of stimuli, such as allergens, tobacco smoke, and lipopolysaccharides [51]. Although the 17q21 polymorphisms which control ORMDL3 expression have not been associated with atopy [42, 45, 52], some seem related to T helper cell type 2 (Th2) cytokine responses [53] and asthmatic responses to allergens [54]. Overexpression of human ORMDL3 in transgenic mice showed an associated increase in airway remodeling (smooth muscle, fibrosis, mucous production) and an enhanced IgE response compared to wild-type mice following allergen challenge [55].

Though the underlying mechanisms functionally linking ORMDL3 to asthma remain largely unknown, a growing body of evidence supports ORMDL3 as contributing to the etiology of asthma, where it likely participates in multiple pathways important to its underlying pathogenesis. In mice, ORMDL3 was shown to be an allergen and Th2 cytokine-inducible gene which regulates the expression of chemokines, metalloproteinases, and oligoadenylate synthetases through activation of the unfolded protein response (UPR). This led to epithelial cell remodeling through its effect on the sarco/endoplasmic reticulum Ca-ATPase (SERCA) [51, 55]. In contrast, a study in human airway epithelial cells did not find inflammation or UPR activation to be associated with ORMDL3 expression [56]. ORMDL3 has also been implicated in endoplasmic reticulum-mediated calcium signaling and stress responses in immune cells [57], as well as in eosinophil trafficking, recruitment, and degranulation in murine models of allergic asthma [58].

ORMDL3, asthma, and sphingolipid metabolism

Another potential mechanism linking ORMDL3 to asthma is through alterations in sphingolipid homeostasis and de novo sphingolipid synthesis. The de novo pathway of sphingolipid synthesis which originates in the endoplasmic reticulum (ER) is a key mechanism for regulating cellular levels of ceramide and other sphingolipids [7]. ORMDL proteins act as inhibitors of serine palmitoyl-CoA transferase (SPT), the rate-limiting enzyme for de novo sphingolipid synthesis [5961], and regulate cellular ceramide levels [22, 61, 62]. ORMDL3 is localized to the ER and is highly expressed in airway epithelial cells [51]. The first step in de novo sphingolipid synthesis begins with the condensation of serine and palmitoyl-CoA by SPT. The reaction product, 3-ketosphinganine, is unstable and is rapidly converted to sphinganine. Sphinganine is further metabolized by distinct ceramide synthases to dihydroceramides which can then generate ceramides via dihydroceramide desaturase [10]. ORMDLs have been shown to mediate the regulation of sphingolipid homeostasis in response to overall cellular sphingolipid levels and maintain physiologic sphingolipid concentrations in the face of external perturbations [6, 59, 6163].

Alteration in de novo sphingolipid synthesis has emerged as a contributing factor in airway hyperreactivity, a cardinal feature of all asthma types. Given that the asthma-associated ORMDL3 polymorphisms lead to increased expression of ORMDL3 [38], it has been suggested that asthma-associated SNPs negatively regulate SPT resulting in inhibited de novo sphingolipid synthesis [64]. How ORMDL3 regulates SPT activity remains largely unknown; however, ORMDL has been shown to form stable complexes with SPT [59, 61], and ORMDL3 expression is dependent on and responsive to the overall SPT activity of the cell [62, 65].

The regulation of sphingolipid metabolism is complex, incompletely understood, and involves a network of multiple interconnected mechanisms [6, 61]. Knockdown of ORMDL1, 2, and 3 in mammalian cells has been shown to increase ceramides [22, 59, 61]; however, the overexpression of ORMDL3 appears to have a differential response. In airway epithelial cell lines, a modest overexpression of ORMDL3 decreases ceramide levels likely due to inhibition of SPT-dependent de novo synthesis. However, robust overexpression of ORMDL3 resulted in overall increased ceramide levels [22, 62] suggesting a possible contribution of the recycling/salvage sphingolipid synthesis pathways [22] and indicating that relative cellular concentrations of SPT and ORMDL are important in the regulation of de novo sphingolipid synthesis by ORMDL expression [62].

In mouse models, airway hyperreactivity has been associated with alterations in de novo sphingolipid synthesis through effects on ORMDL and SPT. In a transgenic mouse model, overexpression of human ORMDL3 showed increased airway responsiveness to methacholine challenge compared to wild-type mice [55]. Decreased de novo sphingolipid synthesis either by direct pharmacologic inhibition with myriocin or genetic haploinsufficiency of SPT increases airway reactivity in the absence of allergic sensitization or inflammation [64]. Increased hyperreactivity was also noted in isolated human bronchial rings which underwent SPT inhibition by myriocin [64]. In an allergic mouse model, inhibition of SPT with myriocin was also associated with the exacerbation of airway hyperreactivity, in recent work by Edukulla and Lindsley [66]. Although the regulation of sphingolipid metabolism is clearly complex, these findings suggest altered sphingolipid homeostasis as an important contributor for asthma pathogenesis [67] and remains an active area of ongoing research.

Conclusions

Sphingolipids, long known as important structural components of the cell, have emerged as important cell signaling molecules regulating a wide range of cellular functions, including cell proliferation and apoptosis, vascular and epithelial integrity, cell contact and adhesion, innate and acquired immunity, and inflammation [6, 7, 68, 69]. The role of sphingolipids and their effects on airway function and disease are highly integrated and complex; though in its early stages, our understanding of these roles is rapidly expanding. The sphingolipid metabolites S1P and ceramides have been implicated in the pathogenesis of pulmonary diseases, including asthma. In addition, alterations in de novo sphingolipid metabolism have been shown to lead to airway hyperreactivity, the cardinal feature of asthma, without allergic sensitization or inflammation. Sphingolipid synthesis thus represents a novel metabolic pathway influencing airway smooth muscle contractility, and strategies to affect sphingolipid homeostasis and metabolism hold promise as novel and more personalized approaches to treat childhood asthma in the future.

Abbreviations

COPD: 

chronic obstructive pulmonary disease

HRV: 

human rhinovirus

IgE: 

immunoglobulin E

ORMDL3: 

orosomucoid-like 3 gene

S1P: 

sphingosine-1-phosphate

SNP: 

single nucleotide polymorphism

SPT: 

serine palmitoyl-CoA transferase

Th2: 

T helper cell type 2

Declarations

Acknowledgements

We thank B. Sung, B.I. Kim, XC-Jiang, and M. Perzanowski for the assistance and critical input with the underlying research studies and Christine and Pasco Alfaro for their generous support. J. Ono is supported by grant KL2TR000458 from the National Center for Advancing Translational Sciences, National Institutes of Health.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

(1)
Department of Pediatrics, Weill Cornell Medical College
(2)
Department of Pathology, Columbia University
(3)
Department of Genetic Medicine, Weill Cornell Medical College

References

  1. Barnett SBL, Nurmagambetov TA (2011) Costs of asthma in the United States: 2002-2007. J Allergy Clin Immunol 127(1):145–152. doi:10.1016/j.jaci.2010.10.020 View ArticlePubMedGoogle Scholar
  2. Gary PA (2008) Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 372(9643):1107–1119. doi:10.1016/s0140-6736(08)61452-x View ArticleGoogle Scholar
  3. Wenzel SE (2012) Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 18(5):716–725. doi:10.1038/nm.2678 View ArticlePubMedGoogle Scholar
  4. McGrath KW, Icitovic N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM, Fahy JV (2012) A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 185(6):612–619. doi:10.1164/rccm.201109-1640OC PubMed CentralView ArticlePubMedGoogle Scholar
  5. Paul MOB (2011) Therapeutic strategies to reduce asthma exacerbations. J Allergy Clin Immunol Pract 128(2):257–263. doi:10.1016/j.jaci.2011.03.035 View ArticleGoogle Scholar
  6. Breslow DK, Weissman JS (2010) Membranes in balance: mechanisms of sphingolipid homeostasis. Mol Cell 40(2):267–279PubMed CentralView ArticlePubMedGoogle Scholar
  7. Hannun YA, Obeid LM (2008) Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9(2):139–150View ArticlePubMedGoogle Scholar
  8. Yang Y, Uhlig S (2011) The role of sphingolipids in respiratory disease. Ther Adv Respir Dis 5(5):325–344. doi:10.1177/1753465811406772 View ArticlePubMedGoogle Scholar
  9. Merrill AH Jr, Sandhoff K, Vance DE, Vance JE (2002) Chapter 14 Sphingolipids: metabolism and cell signaling. In: New Comprehensive Biochemistry, vol 36. Elsevier, Amsterdam, pp 373–407. doi:10.1016/s0167-7306(02)36016-2 Google Scholar
  10. Gault CR, Obeid LM, Hannun YA (2010) An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol 688:1–23PubMed CentralView ArticlePubMedGoogle Scholar
  11. Ammit AJ, Hastie AT, Edsall LC, Hoffman RK, Amrani Y, Krymskaya VP, Kane SA, Peters SP, Penn RB, Spiegel S, Panettieri RA Jr (2001) Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma. FASEB J 15(7):1212–1214PubMedGoogle Scholar
  12. Ble FX, Cannet C, Zurbruegg S, Gerard C, Frossard N, Beckmann N, Trifilieff A (2009) Activation of the lung S1P(1) receptor reduces allergen-induced plasma leakage in mice. Br J Pharmacol 158(5):1295–1301. doi:10.1111/j.1476-5381.2009.00391.x PubMed CentralView ArticlePubMedGoogle Scholar
  13. Fyrst H, Saba JD (2010) An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol 6(7):489–497. doi:10.1038/nchembio.392 PubMed CentralView ArticlePubMedGoogle Scholar
  14. Jolly PS, Rosenfeldt HM, Milstien S, Spiegel S (2002) The roles of sphingosine-1-phosphate in asthma. Mol Immunol 38(16-18):1239–1245View ArticlePubMedGoogle Scholar
  15. Lai WQ, Goh HH, Bao Z, Wong WS, Melendez AJ, Leung BP (2008) The role of sphingosine kinase in a murine model of allergic asthma. J Immunol 180(6):4323–4329View ArticlePubMedGoogle Scholar
  16. Lai WQ, Wong WS, Leung BP (2011) Sphingosine kinase and sphingosine 1-phosphate in asthma. Biosci Rep 31(2):145–150. doi:10.1042/BSR20100087 View ArticlePubMedGoogle Scholar
  17. Rosenfeldt HM, Amrani Y, Watterson KR, Murthy KS, Panettieri RA Jr, Spiegel S (2003) Sphingosine-1-phosphate stimulates contraction of human airway smooth muscle cells. FASEB J 17(13):1789–1799. doi:10.1096/fj.02-0836com View ArticlePubMedGoogle Scholar
  18. Roviezzo F, D'Agostino B, Brancaleone V, De Gruttola L, Bucci M, De Dominicis G, Orlotti D, D'Aiuto E, De Palma R, Rossi F, Sorrentino R, Cirino G (2010) Systemic administration of sphingosine-1-phosphate increases bronchial hyperresponsiveness in the mouse. Am J Respir Cell Mol Biol 42(5):572–577. doi:10.1165/rcmb.2009-0108OC View ArticlePubMedGoogle Scholar
  19. Sun X, Ma SF, Wade MS, Flores C, Pino-Yanes M, Moitra J, Ober C, Kittles R, Husain AN, Ford JG, Garcia JG (2010) Functional variants of the sphingosine-1-phosphate receptor 1 gene associate with asthma susceptibility. J Allergy Clin Immunol 126(2):241-249, 249 e241-243. doi:10.1016/j.jaci.2010.04.036 View ArticleGoogle Scholar
  20. Nishiuma T, Nishimura Y, Okada T, Kuramoto E, Kotani Y, Jahangeer S, Nakamura S (2008) Inhalation of sphingosine kinase inhibitor attenuates airway inflammation in asthmatic mouse model. Am J Physiol Lung Cell Mol Physiol 294(6):L1085–1093. doi:10.1152/ajplung.00445.2007 View ArticlePubMedGoogle Scholar
  21. Sanchez T, Hla T (2004) Structural and functional characteristics of S1P receptors. J Cell Biochem 92(5):913–922. doi:10.1002/jcb.20127 View ArticlePubMedGoogle Scholar
  22. Oyeniran C, Sturgill JL, Hait NC, Huang WC, Avni D, Maceyka M, Newton J, Allegood JC, Montpetit A, Conrad DH, Milstien S, Spiegel S (2015) Aberrant ORM (yeast)-like protein isoform 3 (ORMDL3) expression dysregulates ceramide homeostasis in cells and ceramide exacerbates allergic asthma in mice. J Allergy Clin Immunol. doi:10.1016/j.jaci.2015.02.031 PubMedGoogle Scholar
  23. Kume H, Takeda N, Oguma T, Ito S, Kondo M, Ito Y, Shimokata K (2007) Sphingosine 1-phosphate causes airway hyper-reactivity by rho-mediated myosin phosphatase inactivation. J Pharmacol Exp Ther 320(2):766–773. doi:10.1124/jpet.106.110718 View ArticlePubMedGoogle Scholar
  24. Jolly PS, Bektas M, Olivera A, Gonzalez-Espinosa C, Proia RL, Rivera J, Milstien S, Spiegel S (2004) Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is required for normal mast cell degranulation and chemotaxis. J Exp Med 199(7):959–970. doi:10.1084/jem.20030680 PubMed CentralView ArticlePubMedGoogle Scholar
  25. Oskeritzian CA, Milstien S, Spiegel S (2007) Sphingosine-1-phosphate in allergic responses, asthma and anaphylaxis. Pharmacol Ther 115(3):390–399. doi:10.1016/j.pharmthera.2007.05.011 PubMed CentralView ArticlePubMedGoogle Scholar
  26. Rivera J, Gilfillan AM (2006) Molecular regulation of mast cell activation. J Allergy Clin Immunol 117(6):1214–1225. doi:10.1016/j.jaci.2006.04.015, quiz 1226View ArticlePubMedGoogle Scholar
  27. Postma DS, Rabe KF (2015) The Asthma-COPD Overlap Syndrome. N Engl J Med 373(13):1241–1249. doi:10.1056/NEJMra1411863 View ArticlePubMedGoogle Scholar
  28. Friedlander AL, Lynch D, Dyar LA, Bowler RP (2007) Phenotypes of chronic obstructive pulmonary disease. COPD 4(4):355–384. doi:10.1080/15412550701629663 View ArticlePubMedGoogle Scholar
  29. Telenga ED, Hoffmann RF, Ruben t’K, Hoonhorst SJ, Willemse BW, van Oosterhout AJ, Heijink IH, van den Berge M, Jorge L, Sandra P, Postma DS, Sandra K, ten Hacken NH (2014) Untargeted lipidomic analysis in chronic obstructive pulmonary disease. Uncovering sphingolipids. Am J Respir Crit Care Med 190(2):155–164. doi:10.1164/rccm.201312-2210OC View ArticlePubMedGoogle Scholar
  30. Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, Cho C, Hubbard WC, Berdyshev EV, Tuder RM (2005) Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med 11(5):491–498PubMed CentralView ArticlePubMedGoogle Scholar
  31. Bowler RP, Jacobson S, Cruickshank C, Hughes GJ, Siska C, Ory DS, Petrache I, Schaffer JE, Reisdorph N, Kechris K (2015) Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes. Am J Respir Crit Care Med 191(3):275–284. doi:10.1164/rccm.201410-1771OC View ArticlePubMedGoogle Scholar
  32. Binia A, Khorasani N, Bhavsar PK, Adcock I, Brightling CE, Chung KF, Cookson WO, Moffatt MF (2011) Chromosome 17q21 SNP and severe asthma. J Hum Genet 56(1):97–98. doi:10.1038/jhg.2010.134 PubMed CentralView ArticlePubMedGoogle Scholar
  33. Bisgaard H, Bonnelykke K, Sleiman PM, Brasholt M, Chawes B, Kreiner-Moller E, Stage M, Kim C, Tavendale R, Baty F, Pipper CB, Palmer CN, Hakonarsson H (2009) Chromosome 17q21 gene variants are associated with asthma and exacerbations but not atopy in early childhood. Am J Respir Crit Care Med 179(3):179–185View ArticlePubMedGoogle Scholar
  34. Bouzigon E, Corda E, Aschard H, Dizier MH, Boland A, Bousquet J, Chateigner N, Gormand F, Just J, Le Moual N, Scheinmann P, Siroux V, Vervloet D, Zelenika D, Pin I, Kauffmann F, Lathrop M, Demenais F (2008) Effect of 17q21 variants and smoking exposure in early-onset asthma. N Engl J Med 359(19):1985–1994. doi:10.1056/NEJMoa0806604 View ArticlePubMedGoogle Scholar
  35. Galanter J, Choudhry S, Eng C, Nazario S, Rodriguez-Santana JR, Casal J, Torres-Palacios A, Salas J, Chapela R, Watson HG, Meade K, LeNoir M, Rodriguez-Cintron W, Avila PC, Burchard EG (2008) ORMDL3 gene is associated with asthma in three ethnically diverse populations. Am J Respir Crit Care Med 177(11):1194–1200PubMed CentralView ArticlePubMedGoogle Scholar
  36. Halapi E, Gudbjartsson DF, Jonsdottir GM, Bjornsdottir US, Thorleifsson G, Helgadottir H, Williams C, Koppelman GH, Heinzmann A, Boezen HM, Jonasdottir A, Blondal T, Gudjonsson SA, Thorlacius T, Henry AP, Altmueller J, Krueger M, Shin HD, Uh ST, Cheong HS, Jonsdottir B, Ludviksson BR, Ludviksdottir D, Gislason D, Park CS, Deichmann K, Thompson PJ, Wjst M, Hall IP, Postma DS, Gislason T, Kong A, Jonsdottir I, Thorsteinsdottir U, Stefansson K (2010) A sequence variant on 17q21 is associated with age at onset and severity of asthma. Eur J Hum Genet 18(8):902–908. doi:10.1038/ejhg.2010.38 PubMed CentralView ArticlePubMedGoogle Scholar
  37. Hirota T, Harada M, Sakashita M, Doi S, Miyatake A, Fujita K, Enomoto T, Ebisawa M, Yoshihara S, Noguchi E, Saito H, Nakamura Y, Tamari M (2008) Genetic polymorphism regulating ORM1-like 3 (Saccharomyces cerevisiae) expression is associated with childhood atopic asthma in a Japanese population. J Allergy Clin Immunol 121(3):769–770. doi:10.1016/j.jaci.2007.09.038 View ArticlePubMedGoogle Scholar
  38. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, Depner M, von Berg A, Bufe A, Rietschel E, Heinzmann A, Simma B, Frischer T, Willis-Owen SAG, Wong KCC, Illig T, Vogelberg C, Weiland SK, von Mutius E, Abecasis GR, Farrall M, Gut IG, Lathrop GM, Cookson WOC (2007) Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 448(7152):470–473View ArticlePubMedGoogle Scholar
  39. Sleiman PM, Annaiah K, Imielinski M, Bradfield JP, Kim CE, Frackelton EC, Glessner JT, Eckert AW, Otieno FG, Santa E, Thomas K, Smith RM, Glaberson W, Garris M, Gunnlaugsson S, Chiavacci RM, Allen J, Spergel J, Grundmeier R, Grunstein MM, Magnusson M, Bisgaard H, Grant SF, Hakonarson H (2008) ORMDL3 variants associated with asthma susceptibility in North Americans of European ancestry. J Allergy Clin Immunol 122(6):1225–1227View ArticlePubMedGoogle Scholar
  40. Smit LA, Bouzigon E, Pin I, Siroux V, Monier F, Aschard H, Bousquet J, Gormand F, Just J, Le Moual N, Nadif R, Scheinmann P, Vervloet D, Lathrop M, Demenais F, Kauffmann F (2010) 17q21 variants modify the association between early respiratory infections and asthma. Eur Respir J 36(1):57–64. doi:10.1183/09031936.00154509 View ArticlePubMedGoogle Scholar
  41. Tavendale R, Macgregor DF, Mukhopadhyay S, Palmer CN (2008) A polymorphism controlling ORMDL3 expression is associated with asthma that is poorly controlled by current medications. J Allergy Clin Immunol 121(4):860–863View ArticlePubMedGoogle Scholar
  42. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, von Mutius E, Farrall M, Lathrop M, Cookson WO (2010) A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 363(13):1211–1221. doi:10.1056/NEJMoa0906312 PubMed CentralView ArticlePubMedGoogle Scholar
  43. Caliskan M, Bochkov YA, Kreiner-Moller E, Bonnelykke K, Stein MM, Du G, Bisgaard H, Jackson DJ, Gern JE, Lemanske RF Jr, Nicolae DL, Ober C (2013) Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. N Engl J Med 368(15):1398–1407. doi:10.1056/NEJMoa1211592 PubMed CentralView ArticlePubMedGoogle Scholar
  44. Leusink M, Vijverberg SJ, Koenderman L, Raaijmakers JA, de Jongste JC, Sterk PJ, Duiverman EJ, Onland-Moret NC, Postma DS, de Boer A, de Bakker PI, Koppelman GH, Maitland-van der Zee AH (2015) Genetic variation in uncontrolled childhood asthma despite ICS treatment. Pharmacogenomics J. doi:10.1038/tpj.2015.36 PubMedGoogle Scholar
  45. Granell R, Henderson AJ, Timpson N, St Pourcain B, Kemp JP, Ring SM, Ho K, Montgomery SB, Dermitzakis ET, Evans DM, Sterne JA (2013) Examination of the relationship between variation at 17q21 and childhood wheeze phenotypes. J Allergy Clin Immunol 131(3):685–694. doi:10.1016/j.jaci.2012.09.021 PubMed CentralView ArticlePubMedGoogle Scholar
  46. Toncheva AA, Potaczek DP, Schedel M, Gersting SW, Michel S, Krajnov N, Gaertner VD, Klingbeil JM, Illig T, Franke A, Winkler C, Hohlfeld JM, Vogelberg C, von Berg A, Bufe A, Heinzmann A, Laub O, Rietschel E, Simma B, Genuneit J, Muntau AC, Kabesch M (2015) Childhood asthma is associated with mutations and gene expression differences of ORMDL genes which can interact. Allergy. doi:10.1111/all.12652 PubMedGoogle Scholar
  47. Wan YI, Shrine NR, Soler Artigas M, Wain LV, Blakey JD, Moffatt MF, Bush A, Chung KF, Cookson WO, Strachan DP, Heaney L, Al-Momani BA, Mansur AH, Manney S, Thomson NC, Chaudhuri R, Brightling CE, Bafadhel M, Singapuri A, Niven R, Simpson A, Holloway JW, Howarth PH, Hui J, Musk AW, James AL, Australian Asthma Genetics C, Brown MA, Baltic S, Ferreira MA, Thompson PJ, Tobin MD, Sayers I, Hall IP (2012) Genome-wide association study to identify genetic determinants of severe asthma. Thorax 67(9):762–768. doi:10.1136/thoraxjnl-2011-201262 View ArticlePubMedGoogle Scholar
  48. Gern JE (2015) How rhinovirus infections cause exacerbations of asthma. Clin Exp Allergy 45(1):32–42. doi:10.1111/cea.12428 View ArticlePubMedGoogle Scholar
  49. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, Symington P, O'Toole S, Myint SH, Tyrrell DA et al (1995) Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 310(6989):1225–1229PubMed CentralView ArticlePubMedGoogle Scholar
  50. Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, Printz MC, Lee WM, Shult PA, Reisdorf E, Carlson-Dakes KT, Salazar LP, DaSilva DF, Tisler CJ, Gern JE, Lemanske RF Jr (2008) Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med 178(7):667–672. doi:10.1164/rccm.200802-309OC PubMed CentralView ArticlePubMedGoogle Scholar
  51. Miller M, Tam AB, Cho JY, Doherty TA, Pham A, Khorram N, Rosenthal P, Mueller JL, Hoffman HM, Suzukawa M, Niwa M, Broide DH (2012) ORMDL3 is an inducible lung epithelial gene regulating metalloproteases, chemokines, OAS, and ATF6. Proc Natl Acad Sci U S A 109(41):16648–16653. doi:10.1073/pnas.1204151109 PubMed CentralView ArticlePubMedGoogle Scholar
  52. Ober C, Yao TC (2011) The genetics of asthma and allergic disease: a 21st century perspective. Immunol Rev 242(1):10–30. doi:10.1111/j.1600-065X.2011.01029.x PubMed CentralView ArticlePubMedGoogle Scholar
  53. Schedel M, Michel S, Gaertner VD, Toncheva AA, Depner M, Binia A, Schieck M, Rieger MT, Klopp N, von Berg A, Bufe A, Laub O, Rietschel E, Heinzmann A, Simma B, Vogelberg C, Genuneit J, Illig T, Kabesch M (2015) Polymorphisms related to ORMDL3 are associated with asthma susceptibility, alterations in transcriptional regulation of ORMDL3, and changes in T2 cytokine levels. J Allergy Clin Immunol. doi:10.1016/j.jaci.2015.03.014 PubMedGoogle Scholar
  54. Lluis A, Schedel M, Liu J, Illi S, Depner M, von Mutius E, Kabesch M, Schaub B (2011) Asthma-associated polymorphisms in 17q21 influence cord blood ORMDL3 and GSDMA gene expression and IL-17 secretion. J Allergy Clin Immunol 127(6):1587–1594. doi:10.1016/j.jaci.2011.03.015, e1586View ArticlePubMedGoogle Scholar
  55. Miller M, Rosenthal P, Beppu A, Mueller JL, Hoffman HM, Tam AB, Doherty TA, McGeough MD, Pena CA, Suzukawa M, Niwa M, Broide DH (2014) ORMDL3 transgenic mice have increased airway remodeling and airway responsiveness characteristic of asthma. J Immunol. doi:10.4049/jimmunol.1303047 Google Scholar
  56. Hsu KJ, Turvey SE (2013) Functional analysis of the impact of ORMDL3 expression on inflammation and activation of the unfolded protein response in human airway epithelial cells. Allergy Asthma Clin Immunol 9(1):4. doi:10.1186/1710-1492-9-4 PubMed CentralView ArticlePubMedGoogle Scholar
  57. Cantero-Recasens G, Fandos C, Rubio-Moscardo F, Valverde MA, Rn V (2010) The asthma-associated ORMDL3 gene product regulates endoplasmic reticulum-mediated calcium signaling and cellular stress. Hum Mol Genet 19(1):111–121View ArticlePubMedGoogle Scholar
  58. Ha SG, Ge XN, Bahaie NS, Kang BN, Rao A, Rao SP, Sriramarao P (2013) ORMDL3 promotes eosinophil trafficking and activation via regulation of integrins and CD48. Nat Commun 4:2479. doi:10.1038/ncomms3479 PubMed CentralView ArticlePubMedGoogle Scholar
  59. Breslow DK, Collins SR, Bodenmiller B, Aebersold R, Simons K, Shevchenko A, Ejsing CS, Weissman JS (2010) Orm family proteins mediate sphingolipid homeostasis. Nature 463(7284):1048–1053PubMed CentralView ArticlePubMedGoogle Scholar
  60. Han S, Lone MA, Schneiter R, Chang A (2010) Orm1 and Orm2 are conserved endoplasmic reticulum membrane proteins regulating lipid homeostasis and protein quality control. Proc Natl Acad Sci USA 107(13):5851–5856PubMed CentralView ArticlePubMedGoogle Scholar
  61. Siow DL, Wattenberg BW (2012) Mammalian ORMDL proteins mediate the feedback response in ceramide biosynthesis. J Biol Chem 287(48):40198–40204. doi:10.1074/jbc.C112.404012 PubMed CentralView ArticlePubMedGoogle Scholar
  62. Siow D, Sunkara M, Dunn-Giroux TM, Morris AJ, Wattenberg B (2015) ORMDL/serine palmitoyltransferase stoichiometry determines effects of ORMDL3 expression on sphingolipid biosynthesis. J Lipid Res. doi:10.1194/jlr.M057539 PubMedGoogle Scholar
  63. Sun Y, Miao Y, Yamane Y, Zhang C, Shokat KM, Takematsu H, Kozutsumi Y, Drubin DG (2012) Orm protein phosphoregulation mediates transient sphingolipid biosynthesis response to heat stress via the Pkh-Ypk and Cdc55-PP2A pathways. Mol Biol Cell. doi:10.1091/mbc.E12-03-0209 Google Scholar
  64. Worgall TS, Veerappan A, Sung B, Kim BI, Weiner E, Bholah R, Silver RB, Jiang XC, Worgall S (2013) Impaired sphingolipid synthesis in the respiratory tract induces airway hyperreactivity. Sci Transl Med 5(186):186ra167. doi:10.1126/scitranslmed.3005765 View ArticleGoogle Scholar
  65. Gupta SD, Gable K, Alexaki A, Chandris P, Proia RL, Dunn TM, Harmon JM (2015) Expression of the ORMDLS, modulators of serine palmitoyltransferase, is regulated by sphingolipids in mammalian cells. J Biol Chem 290(1):90–98. doi:10.1074/jbc.M114.588236 View ArticlePubMedGoogle Scholar
  66. Edukulla RRK, Lindsley AW (2015) Depletion of sphingolipids in a murine model of allergic asthma exacerbates airway hyperresponsiveness by increasing Th2 cells. Am J Respir Crit Care Med 191:A6436Google Scholar
  67. Levy BD (2013) Sphingolipids and susceptibility to asthma. N Engl J Med 369(10):976–978. doi:10.1056/NEJMcibr1306864 View ArticlePubMedGoogle Scholar
  68. Maceyka M, Spiegel S (2014) Sphingolipid metabolites in inflammatory disease. Nature 510(7503):58–67. doi:10.1038/nature13475 PubMed CentralView ArticlePubMedGoogle Scholar
  69. Tibboel J, Reiss I, de Jongste JC, Post M (2014) Sphingolipids in lung growth and repair. Chest 145(1):120–128. doi:10.1378/chest.13-0967 View ArticlePubMedGoogle Scholar

Copyright

© Ono et al. 2015